Cited by

• Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo.

  Weiss C, Uziel O, Wolach O, Nordenberg J, Beery E, Bulvick S, Kanfer G, Cohen O, Ram R, Bakhanashvili M, Magen-Nativ H, Shilo N, Lahav M. Weiss C, et al. Br J Cancer. 2012 Nov 20;107(11):1844-52. doi: 10.1038/bjc.2012.460. Br J Cancer. 2012. PMID: 23169337 Free PMC article.
• Bone marrow-derived mesenchymal stem cells inhibit CD8⁺ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.

  Liu Z, Mi F, Han M, Tian M, Deng L, Meng N, Luo J, Fu R. Liu Z, et al. Clin Exp Immunol. 2021 Jul;205(1):53-62. doi: 10.1111/cei.13594. Epub 2021 May 7. Clin Exp Immunol. 2021. PMID: 33735518 Free PMC article.
• The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment.

  Jurczyszyn A, Czepiel J, Gdula-Argasińska J, Perucki W, Skotnicki AB, Majka M. Jurczyszyn A, et al. J Cancer. 2015 Jan 5;6(2):160-8. doi: 10.7150/jca.10873. eCollection 2015. J Cancer. 2015. PMID: 25561981 Free PMC article.
• The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease.

  Dotterweich J, Tower RJ, Brandl A, Müller M, Hofbauer LC, Beilhack A, Ebert R, Glüer CC, Tiwari S, Schütze N, Jakob F. Dotterweich J, et al. PLoS One. 2016 May 9;11(5):e0155087. doi: 10.1371/journal.pone.0155087. eCollection 2016. PLoS One. 2016. PMID: 27158817 Free PMC article.
• Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.

  Jurczyszyn A, Zebzda A, Czepiel J, Perucki W, Bazan-Socha S, Cibor D, Owczarek D, Majka M. Jurczyszyn A, et al. J Cancer. 2014 May 31;5(6):480-90. doi: 10.7150/jca.8731. eCollection 2014. J Cancer. 2014. PMID: 24959301 Free PMC article.